Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/MAP2K5_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MAP2K5_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MAP2K5_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAP2K5_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MAP2K5_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:2000117110 | Esophagus | ESCC | negative regulation of cysteine-type endopeptidase activity | 63/8552 | 86/18723 | 1.84e-07 | 2.88e-06 | 63 |
GO:0043154110 | Esophagus | ESCC | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 58/8552 | 78/18723 | 2.38e-07 | 3.61e-06 | 58 |
GO:2001237111 | Esophagus | ESCC | negative regulation of extrinsic apoptotic signaling pathway | 69/8552 | 97/18723 | 3.23e-07 | 4.55e-06 | 69 |
GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
GO:00719029 | Esophagus | ESCC | positive regulation of protein serine/threonine kinase activity | 124/8552 | 200/18723 | 2.27e-06 | 2.61e-05 | 124 |
GO:00607595 | Esophagus | ESCC | regulation of response to cytokine stimulus | 103/8552 | 162/18723 | 3.14e-06 | 3.53e-05 | 103 |
GO:00380347 | Esophagus | ESCC | signal transduction in absence of ligand | 48/8552 | 65/18723 | 3.63e-06 | 3.97e-05 | 48 |
GO:00971927 | Esophagus | ESCC | extrinsic apoptotic signaling pathway in absence of ligand | 48/8552 | 65/18723 | 3.63e-06 | 3.97e-05 | 48 |
GO:00073698 | Esophagus | ESCC | gastrulation | 115/8552 | 185/18723 | 4.35e-06 | 4.64e-05 | 115 |
GO:004586018 | Esophagus | ESCC | positive regulation of protein kinase activity | 219/8552 | 386/18723 | 6.91e-06 | 6.97e-05 | 219 |
GO:003367420 | Esophagus | ESCC | positive regulation of kinase activity | 260/8552 | 467/18723 | 7.26e-06 | 7.22e-05 | 260 |
GO:003030710 | Esophagus | ESCC | positive regulation of cell growth | 100/8552 | 166/18723 | 1.07e-04 | 7.55e-04 | 100 |
GO:0045861111 | Esophagus | ESCC | negative regulation of proteolysis | 195/8552 | 351/18723 | 1.13e-04 | 7.85e-04 | 195 |
GO:005067318 | Esophagus | ESCC | epithelial cell proliferation | 238/8552 | 437/18723 | 1.19e-04 | 8.20e-04 | 238 |
GO:0051346110 | Esophagus | ESCC | negative regulation of hydrolase activity | 208/8552 | 379/18723 | 1.76e-04 | 1.14e-03 | 208 |
GO:005067817 | Esophagus | ESCC | regulation of epithelial cell proliferation | 206/8552 | 381/18723 | 5.51e-04 | 3.02e-03 | 206 |
GO:002240720 | Esophagus | ESCC | regulation of cell-cell adhesion | 239/8552 | 448/18723 | 5.88e-04 | 3.19e-03 | 239 |
GO:00434055 | Esophagus | ESCC | regulation of MAP kinase activity | 102/8552 | 177/18723 | 8.89e-04 | 4.55e-03 | 102 |
GO:20012394 | Esophagus | ESCC | regulation of extrinsic apoptotic signaling pathway in absence of ligand | 30/8552 | 43/18723 | 1.21e-03 | 5.88e-03 | 30 |
GO:000166720 | Esophagus | ESCC | ameboidal-type cell migration | 250/8552 | 475/18723 | 1.22e-03 | 5.97e-03 | 250 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0472214 | Cervix | CC | Neurotrophin signaling pathway | 32/1267 | 119/8465 | 5.01e-04 | 2.42e-03 | 1.43e-03 | 32 |
hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa04540 | Cervix | CC | Gap junction | 22/1267 | 88/8465 | 9.07e-03 | 2.85e-02 | 1.69e-02 | 22 |
hsa049218 | Cervix | CC | Oxytocin signaling pathway | 34/1267 | 154/8465 | 1.12e-02 | 3.42e-02 | 2.02e-02 | 34 |
hsa05418110 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0472215 | Cervix | CC | Neurotrophin signaling pathway | 32/1267 | 119/8465 | 5.01e-04 | 2.42e-03 | 1.43e-03 | 32 |
hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa045401 | Cervix | CC | Gap junction | 22/1267 | 88/8465 | 9.07e-03 | 2.85e-02 | 1.69e-02 | 22 |
hsa0492111 | Cervix | CC | Oxytocin signaling pathway | 34/1267 | 154/8465 | 1.12e-02 | 3.42e-02 | 2.02e-02 | 34 |
hsa04722 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa05418 | Colorectum | AD | Fluid shear stress and atherosclerosis | 54/2092 | 139/8465 | 1.41e-04 | 1.16e-03 | 7.37e-04 | 54 |
hsa047221 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa054181 | Colorectum | AD | Fluid shear stress and atherosclerosis | 54/2092 | 139/8465 | 1.41e-04 | 1.16e-03 | 7.37e-04 | 54 |
hsa054184 | Colorectum | MSS | Fluid shear stress and atherosclerosis | 51/1875 | 139/8465 | 6.06e-05 | 5.80e-04 | 3.55e-04 | 51 |
hsa047224 | Colorectum | MSS | Neurotrophin signaling pathway | 45/1875 | 119/8465 | 7.04e-05 | 6.55e-04 | 4.02e-04 | 45 |
hsa054185 | Colorectum | MSS | Fluid shear stress and atherosclerosis | 51/1875 | 139/8465 | 6.06e-05 | 5.80e-04 | 3.55e-04 | 51 |
hsa047225 | Colorectum | MSS | Neurotrophin signaling pathway | 45/1875 | 119/8465 | 7.04e-05 | 6.55e-04 | 4.02e-04 | 45 |
hsa054188 | Colorectum | FAP | Fluid shear stress and atherosclerosis | 45/1404 | 139/8465 | 3.05e-06 | 4.63e-05 | 2.81e-05 | 45 |
hsa047226 | Colorectum | FAP | Neurotrophin signaling pathway | 38/1404 | 119/8465 | 2.49e-05 | 2.78e-04 | 1.69e-04 | 38 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | AZD6244 | SELUMETINIB | |
5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | SELUMETINIB | SELUMETINIB | |
5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | | WX-554 | WX-554 | |
5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | TRAMETINIB | TRAMETINIB | |
5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | 328083482 | | |
5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | MEK162 | BINIMETINIB | |
5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | DABRAFENIB MESYLATE | | |
5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | 249565744 | | |
5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | GDC-0973 | COBIMETINIB | |
5607 | MAP2K5 | KINASE, SERINE THREONINE KINASE, TYROSINE KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | BAY869766 | | |